FATE - Fate Therapeutics prices equity offering and pre-funded warrants

Fate Therapeutics (FATE) has priced public offering of ~4.42M shares at $85.50/share and pre-funded warrants to purchase 257,310 common shares at $85.499 per pre-funded warrant, for total gross proceeds of ~$400M.Underwriters' over-allotment is an additional 701,754 shares.Proceeds expected to be ~$376M and will be utilised to fund clinical trials and nonclinical studies of product candidates, the manufacture of clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning and qualification of new facility, the conduct of preclinical research and development, and for general corporate purposes.Offering is expected to close on January 8.Previously: Fate Therapeutics under pressure on underwritten public offering (Jan. 4)

For further details see:

Fate Therapeutics prices equity offering and pre-funded warrants